HUT71324A - Peptide inhibitors of mitogenesis and motogenesis - Google Patents

Peptide inhibitors of mitogenesis and motogenesis

Info

Publication number
HUT71324A
HUT71324A HU9500919A HU9500919A HUT71324A HU T71324 A HUT71324 A HU T71324A HU 9500919 A HU9500919 A HU 9500919A HU 9500919 A HU9500919 A HU 9500919A HU T71324 A HUT71324 A HU T71324A
Authority
HU
Hungary
Prior art keywords
motogenesis
mitogenesis
peptide inhibitors
peptide
inhibitors
Prior art date
Application number
HU9500919A
Other languages
English (en)
Other versions
HU219813B (hu
HU9500919D0 (en
Inventor
Paolo Comoglio
Carola Ponzetto
Original Assignee
Pharmacia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313528A external-priority patent/GB9313528D0/en
Priority claimed from GB9407673A external-priority patent/GB9407673D0/en
Application filed by Pharmacia Spa filed Critical Pharmacia Spa
Publication of HU9500919D0 publication Critical patent/HU9500919D0/hu
Publication of HUT71324A publication Critical patent/HUT71324A/hu
Publication of HU219813B publication Critical patent/HU219813B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU9500919A 1993-06-30 1994-06-15 Mitogenezis és motogenezis peptid inhibitorok HU219813B (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939313528A GB9313528D0 (en) 1993-06-30 1993-06-30 Peptide inhibitors of mitogenesis and motogenesis
GB9407673A GB9407673D0 (en) 1994-04-18 1994-04-18 Peptide inhibitors of mitogenesis and motogenius
PCT/EP1994/001943 WO1995001376A1 (en) 1993-06-30 1994-06-15 Peptide inhibitors of mitogenesis and motogenesis

Publications (3)

Publication Number Publication Date
HU9500919D0 HU9500919D0 (en) 1995-05-29
HUT71324A true HUT71324A (en) 1995-11-28
HU219813B HU219813B (hu) 2001-08-28

Family

ID=26303150

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9500919A HU219813B (hu) 1993-06-30 1994-06-15 Mitogenezis és motogenezis peptid inhibitorok

Country Status (15)

Country Link
US (2) US5594105A (hu)
EP (1) EP0662090A1 (hu)
JP (1) JP3585044B2 (hu)
KR (1) KR950703003A (hu)
CN (1) CN1056153C (hu)
AU (1) AU670704B2 (hu)
CA (1) CA2142713A1 (hu)
FI (1) FI950729A (hu)
HU (1) HU219813B (hu)
IL (1) IL110160A (hu)
MY (1) MY130026A (hu)
NZ (1) NZ268006A (hu)
PL (1) PL179628B1 (hu)
RU (1) RU2146262C1 (hu)
WO (1) WO1995001376A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512704A (ja) * 1994-03-17 1997-12-22 ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン シグナル変換経路を調節するための産物および方法
US5744313A (en) * 1994-12-09 1998-04-28 The Regents Of The University Of California Assay employing novel protein domain which binds tyrosine phosphorylated proteins
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6107457A (en) * 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
GB9603227D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
CA2368733C (en) * 1999-03-23 2014-10-07 Terrence R. Burke, Jr. Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US7132392B1 (en) 1999-10-22 2006-11-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
EP1383792A2 (en) * 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Sh2 domain binding inhibitors
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
JP4694786B2 (ja) * 2002-03-01 2011-06-08 ロジャー・ウィリアムズ・ホスピタル 乳房、前立腺および卵巣の癌の予測のための、Ｓｈｃタンパク質に関連する方法および組成物
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
AU2003286411A1 (en) 2002-12-12 2004-06-30 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
WO2004094463A2 (en) * 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
RS51326B (sr) 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
KR101259655B1 (ko) 2005-04-15 2013-04-30 제넨테크, 인크. Ｈｇｆ 베타 사슬 변이체
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
BRPI0818039A2 (pt) * 2007-10-15 2014-10-14 Chugai Pharmaceutical Co Ltd Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas.
IT1397873B1 (it) * 2008-09-30 2013-02-04 Multimedica Holding S P A Uso di peptidi nella terapia antiangiogenica relativa a patologie tumorali
IT1397874B1 (it) * 2008-09-30 2013-02-04 Multimedica Holding S P A Uso di peptidi nella terapia antiangiogenica
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
CN105597078B (zh) * 2014-05-29 2019-01-25 深圳市盛景基因医疗有限公司 一种治疗癌症的肽变体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
ES2104914T3 (es) * 1991-05-10 1997-10-16 Pharmacia & Upjohn Spa Formas truncadas del factor de crecimiento de hepatocitos (hgf).
DE4136443A1 (de) * 1991-11-06 1993-05-13 Boehringer Ingelheim Int Expression der reifen proteinase 2a, ihre partielle reinigung und bereitstellung kompetitiv wirkender substrate
US7642971B2 (en) * 2007-05-25 2010-01-05 Sony Ericsson Mobile Communications Ab Compact diversity antenna arrangement

Also Published As

Publication number Publication date
AU7071894A (en) 1995-01-24
CN1111455A (zh) 1995-11-08
NZ268006A (en) 1996-09-25
IL110160A (en) 2000-06-29
PL179628B1 (pl) 2000-10-31
FI950729A (fi) 1995-04-19
RU2146262C1 (ru) 2000-03-10
HU219813B (hu) 2001-08-28
US5594105A (en) 1997-01-14
KR950703003A (ko) 1995-08-23
RU95108385A (ru) 1997-03-20
HU9500919D0 (en) 1995-05-29
IL110160A0 (en) 1994-10-07
AU670704B2 (en) 1996-07-25
JP3585044B2 (ja) 2004-11-04
EP0662090A1 (en) 1995-07-12
JPH08500845A (ja) 1996-01-30
US5912183A (en) 1999-06-15
PL307742A1 (en) 1995-06-12
MY130026A (en) 2007-05-31
FI950729A0 (fi) 1995-02-17
CN1056153C (zh) 2000-09-06
CA2142713A1 (en) 1995-01-12
WO1995001376A1 (en) 1995-01-12

Similar Documents

Publication Publication Date Title
HU9500919D0 (en) Peptide inhibitors of mitogenesis and motogenesis
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
PL314838A1 (en) Inhibitors of bp-iv-serine protease
IL110525A0 (en) Identification and use of protease inhibitors
PL310897A1 (en) Analogues of yy peptide and their application
GB2275380B (en) VCR and method of displaying time thereof
PL327569A1 (en) Promedications of thrombosin inhibitors
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
PL308553A1 (en) Inhibitors of farnesil-protein transferase
GB9227026D0 (en) Dual inhibitors of no synthase and cycloosygenase
IL103772A0 (en) Bloodbag and method of making same
HU9402361D0 (en) New makrolides and use of them
PL298080A1 (en) Novel drivatives of 2-ketoqvinoline and method of obtaining sames
EP0702080A3 (en) Azeotropic compositions containing octamethyltrisiloxane and n-propoxypropanol
PL311300A1 (en) 4-arylo-4-hydroxy-tetrahydropyranes and 3-arylo-3-hydroxy-tetrahydrofuranes as inhibitors of 5-lipoxygenase
NZ328895A (en) Peptide antagonists containing phosphotyrosine or phosphophenylalanine derivatives of cellular mitogenesis and motogenesis
HU9600227D0 (en) Use of amides of phenyl-cyclohexyl-carboxylic acids
PL305160A1 (en) Method of obtaining a modified politetrafluoroethylene and its application
EP0713496A4 (en) THROMBINE INHIBITORS TARGETED ON FIBRIN
PL301204A1 (en) Method of obtaining avermectines and invermectines
EP0854715A4 (en) METHOD FOR INHIBITING THE PLASMINOGEN ACTIVATOR INHIBITOR
ZA944680B (en) Peptide inhibitors of mitogenesis and motogenesis
GB9407673D0 (en) Peptide inhibitors of mitogenesis and motogenius
GB2275314B (en) Support member and method of use
HU9402312D0 (en) Identification and use of protease inhibitors

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee